These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10086797)

  • 1. Magnetic resonance imaging in myelofibrosis and essential thrombocythaemia: contribution to differential diagnosis.
    Rozman C; Cervantes F; Rozman M; Mercader JM; Montserrat E
    Br J Haematol; 1999 Mar; 104(3):574-80. PubMed ID: 10086797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
    Lally J; Boasman K; Brown L; Martinelli V; Cappuccio I; Sovani V; Marinaccio C; Crispino JD; Graham C; Rinaldi C
    J Thromb Haemost; 2019 Jun; 17(6):896-900. PubMed ID: 30889303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrosis identified in the bone marrow biopsies of patients with essential thrombocythemia: its incidence and significance for the differential diagnostic considerations.
    Marcinek J; Plank L; Szépe P; Balhárek T
    Cesk Patol; 2008 Jul; 44(3):62-6. PubMed ID: 18783136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Essential thrombocythaemia with aggressive megakaryocytosis after myelofibrotic transformation.
    Sasaki K; Nannya Y; Nakamura Y; Ichikawa M; Ogawa S; Mitani K
    Hematology; 2021 Dec; 26(1):594-600. PubMed ID: 34402416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients.
    Thiele J; Kvasnicka HM
    Histol Histopathol; 2003 Jan; 18(1):93-102. PubMed ID: 12507288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
    Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
    Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
    Mascarenhas J; Lu M; Li T; Petersen B; Hochman T; Najfeld V; Goldberg JD; Hoffman R
    Br J Haematol; 2013 Apr; 161(1):68-75. PubMed ID: 23330839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinico-Pathological Profile And Outcomes Of Patients With Polycythaemia Vera, Essential Thrombocythaemia And Idiopathic Myelofibrosis: A Tertiary Care Center Experience From Southern Pakistan.
    Shaikh MS; Shaikh MU; Adil SN; Khurshid M; Ahmed ZA
    J Ayub Med Coll Abbottabad; 2016; 28(2):293-297. PubMed ID: 28718562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology.
    Gianelli U; Vener C; Raviele PR; Moro A; Savi F; Annaloro C; Somalvico F; Radaelli F; Franco V; Deliliers GL
    Leuk Lymphoma; 2006 Sep; 47(9):1774-81. PubMed ID: 17064987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 study of simtuzumab in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia myelofibrosis.
    Verstovsek S; Savona MR; Mesa RA; Dong H; Maltzman JD; Sharma S; Silverman J; Oh ST; Gotlib J
    Br J Haematol; 2017 Mar; 176(6):939-949. PubMed ID: 28220932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process?
    Slone JS; Smith MC; Seegmiller AC; Sidonio RF; Yang E
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):559-65. PubMed ID: 23799525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
    Herborg LL; Nederby L; Hasselbalch HC; Aggerholm A; Roug AS
    Int J Lab Hematol; 2018 Jun; 40(3):320-325. PubMed ID: 29427319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.
    Thiele J; Kvasnicka HM; Werden C; Zankovich R; Diehl V; Fischer R
    Leuk Lymphoma; 1996 Jul; 22(3-4):303-17. PubMed ID: 8819080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.